Hikma Pharmaceuticals
 |
|
| Public company (: ) | |
| Industry | Pharmaceutical |
| Founded | 1978 |
| Headquarters | Amman, Jordan |
|
Key people
|
Said Darwazah Chairman and CEO |
| Products |
Amoclan Prograf Suprax |
| Revenue | US$1,440 million (2015) |
| US$409 million (2015) | |
| US$254 million (2015) | |
| Website | www.hikma.com |
Hikma Pharmaceuticals is a multinational pharmaceutical company based in London, that manufactures branded and non-branded generic and in-licensed pharmaceutical products. In 2013, Hikma delivered 23% group revenue growth and is the largest regional pharmaceutical company in the MENA region. It was founded in Amman, Jordan in 1978 by Samih Darwazah. It is listed on the and is a constituent of the FTSE 100 Index.
The Company was founded by Samih Darwazah in 1978 in Amman in Jordan. In August 1996 it became the first Arab company to export pharmaceutical products to the United States. It was first listed on the in 2005. Recent acquisitions include Instituto Biochimico Pavese Pharma in Italy in 2005 and Jazeera Pharmaceutical Industries in Saudi Arabia in 2006. In 2007 the Company went on to buy APM in Jordan, Alkan Pharma in Egypt,APM and Al Jazeera Pharma in Saudi Arabia Thymoorgan in Germany and Ribosepharm in Germany. It also acquired Multi-Source Injectables in the USA in October 2010. In May 2011 Hikma Pharmaceuticals PLC complete the acquisition of Baxter Healthcare Corporation's US generic injectables business (Multi-Source Injectables or MSI).
In October 2011, Hikma Pharmaceuticals entered the Moroccan market through the acquisition of Promopharm, the ninth largest pharmaceutical manufacturer in Morocco. Hikma also inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria in 2011. The Algerian pharmaceutical company is Hikma’s second venture in Algeria after Hikma Pharma Algeria.
In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for a FTSE 250 company.
Hikma expanded its existing presence in the Egyptian market through the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) in 2012. In September 2013, Hikma announced expansion into Sub-Saharan Africa with a 50:50 joint venture agreement with MIDROC Pharmaceuticals Limited, to enter the Ethiopian pharmaceutical market
...
Wikipedia